Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.
Follow-Up Questions
AROAF 주식의 가격 성능은 어떻습니까?
AROAF의 현재 가격은 $0.4589이며, 전 거래일에 decreased 0% 하였습니다.
Aroa Biosurgery Ltd의 주요 사업 주제나 업종은 무엇입니까?
Aroa Biosurgery Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Aroa Biosurgery Ltd의 시가총액은 얼마입니까?
Aroa Biosurgery Ltd의 현재 시가총액은 $158.6M입니다
Aroa Biosurgery Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 6명의 분석가가 Aroa Biosurgery Ltd에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 5명의 매수, 2명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
